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Summary.-Antibodies to bleomycin were raised by immunization of sheep and
rabbits with bleomycin-albumin conjugates. The combination of ahigh-titre, high-
avidity sheep antiserum and iodinated bleomycin produced a radioimmunoassay
sensitive to 8 ng of bleomycin per ml of plasma or urine. Untreated specimens
(100 tul) of plasma or urine could be added directly to the assay tubes. The anti-
serum was specific for bleomycin and showed no cross-reaction with other anti-
cancer agents used in combination chemotherapy. Over a concentration range of
20-100 ng/ml, recovery of bleomycin from plasma was 110% and from urine, 93%.
Repeated assay of plasma samples showed a decrease in bleomycin levels unless the
samples were kept at 4°C or below. Assay of bleomycin levels in plasma and urine
from patients under treatment with bleomycin showed similarities with results
reported using a microbiological assay. The radioimmunoassay offers a more
reliable, rapid and sensitive method for the measurement of bleomycin.
BLEOMYCIN (BM) is a group of anti-
neoplastic antibiotics, produced by the
fungus Streptomyces verticillus, the mem-
bers of which are partially polypeptide
in structure (Umezawa, 1973). Although
there are many reported components of
varying activity (Cohen and I, 1976), the
therapeutic preparation consists mainly
of bleomycin A2 and B2. These have
provedparticularly useful inthetreatment
of squamous-cell carcinoma, sarcoma and
malignant lymphoma. The minimal sup-
pressive effect of BM on human bone
marrow is an important attribute, but the
appearance of pulmonary toxicity is a
side effect which is unpredictable at low
dose and increases rapidly with high doses.
Continuous monitoring of the blood levels
of BM during therapy may, therefore, be
of benefit in restricting toxic side effects
whilst maintaining maximal antineo-
plastic activity.
The principal method for BM measure-
ment has been assessment ofthe inhibition
of bacterial growth on culture medium
by the samples under analysis (Ohnuma
et al., 1974). Whilst this technique
possesses sufficient sensitivity for the
estimation of blood and urine BM levels,
the procedure is much more time-con-
suming than radioimmunoassay (RIA).
The comparatively high molecular weight
ofBM and its peptide-like structure confer
the property ofimmunogenicity on protein
conjugates of the drug, which permits
rapid production of anti-BM sera. In
addition, the drug is susceptible to simple
iodination. With these reagents a rapid
RIA procedure can be developed
(Broughton and Strong, 1976).
MATERIALS AND METHODS
Preparation of immunogen.-Bleomycin
sulphate (donated bv Lundbeck Ltd.) was
conjugated to bovine serum albumin (BSA)
by a carbodiimide condensation reaction.
90 mg of BM (Lot UIIAS) and 100 mg of
BSA were dissolved in 5 ml ofdistilled water.
70 mg of ethyl-(dimethyl-amino-propyl)-car-
bodiimide was then added, and the solution
stirred overnight at room temperature.
Unconjugated BM was removed by dialysis
against several changes of 500-ml volumes of
distilled water. The conjugate solution wasRADIOIMMUNOASSAY OF BLEOMYCIN
lyophilized under vacuum. The amount of
BM conjugated was determined by UV
analysis of the amount recovered in the
dialysates, and its subtraction from the
quantity used originally. By this method it
was calculated that the conjugate contained
13 mol BM per mol BSA.
Immunization.-The BM-BSA conjugate
was injected into 2 sheep. 15 mg of conju-
gate and 3 mg BCG vaccine were dissolved in
7-5 sterile water and emulsified with 7*5
Marcol 52/Arlacel A (9:1) and 7-5 ml
Tween 80. 041 ml aliquots of emulsion were
injected intradermally into 40 sites on the
back of one sheep (HP/S/65). 6 x 1-ml
aliquots were injected s.c. into the back and
6 x 0-5-ml aliquots i.m. into the legs of the
second sheep (HP/S/66). Blood was col-
lected at regular intervals from the jugular
vein. The serum was separated and stored,
after the addition of sodium azide to a final
concentration of 0.1%, in a refrigerator at
40C. High-titre antisera were lyophilized
under vacuum inaliquots of 1: 4 dilution with
0-04M phosphate buffer, pH 7-4.
Production of iodinated bleomycin.-The
procedure is essentially that described by
Broughton and Strong (1976). Into a small
glass vial were placed 10 ,ul of a 500-jug/ml
solution of BM in 01M borate buffer, pH 8-6
and 10 ,ul of [1251]Nal (100 mCi/ml). 10 ,ul
of chloramine T solution (5 mg/ml in borate
buffer) were then added and the mixture left
for 1 min at room temperature before the
addition of 10 ,ul of sodium metabisulphite
solution (12 mg/nl in borate buffer).
The reaction mixture was transferred to a
(12 x 1.25) cm Sephadex G-10 column and
eluted with 01M phosphate buffer, pH 7.4,
containing 0a1% gelatin. 1-ml fractions were
collected and 10-,ul aliquots of each fraction
were monitored for radioactivity. Fractions
eluted at the column void volume, and con-
taining the highest level ofradioactivity, were
combined and stored at 4°C until used. The
immunoreactivity of the iodinated material
was stable for at least 4 months.
Assay procedure.-Standard radioimmu-
noassay techniques were employed (Teale et
al., 1975). The assay protocol used is shown
in Table I. The [1251]BM was diluted im-
mediately before use to 1000 ct/s/ml with
assay buffer (01M phosphate, pH 7 4, con-
taining 0.1% gelatin). Antiserum was used
at the dilution (titre) at which 50% of the
label was bound to antibody. Stock stand-
56
ard solutions of BM containing 1 ,tg/ml were
stored at - 200C and diluted before use.
Dextran-coated charcoal (2.5%) was used in
the separation stage, as previously described
(Teale et al., 1975). Unextracted normal
human plasma or urine could be added to the
assay in volumes up to 100 ,u without sig-
nificantly affecting the binding of the label to
antiserum or its sensitive displacement by
drug standards.
Animal experiments.-Two Half-lop rab-
bits (2.5-3.5 kg) were given i.v. doses of BM
by iinjection into the lateral ear veins. On
the first occasion, a dose of 0 5 mg/kg in
saline was given, and after several weeks this
was followed by a second dose of 1-0 mg/kg.
Blood was collected at frequent intervals from
the contralateral ear vein for up to 3 h.
Plasma was analysed for BM content using
the RIA.
RESULTS
Both sheep immunized with BM-BSA
conjugate produced antisera of relatively
high titre. HP/S/65 reached a peak titre
(1/2000 final dilution) at 22 weeks after
immunization. HP/S/66 produced an an-
tibody titre of 1/12000 also at 22 weeks
after priming.
Standard curves were constructed
using the same BM preparation as stan-
dard that had been used both for immuno-
gen preparation and iodination. An ex-
ample of a standard curve produced using
the protocol in Table I is shown in Fig. 1.
By constructing a Scatchard plot from
this standard curve, the avidity constant
of the assay antiserum (HP/S/66-1C) was
calculated as 1 x 1091/mol. Assay sen-
sitivity for BM in plasma was calculated
(Albano and Ekins, 1970) as 8 ng/ml.
Table II lists the compounds tested for
antibody cross-reactivity and found not
to inhibit label from binding to antibody,
even when present in amounts up to 1 ,
per tube (equivalent to 20 ,ug/ml).
BM was added to normal plasma and
urine at several known concentrations
and the specimens assayed on several
occasions. Mean recoveries in the concen-
tration range 20-100 ng/ml were 110 i
4% in plasma and 93 ± 11% in urine.
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TABLE I.-Assay Protocol
Volumes of reagent added (,I)
Reagent
Diluent buffer
Antiserum (1/2000)
[125I]BM (750 pg)
BM standard
Normal plasma
Plasma sample
Charcoal
Total- Non-specific-
counts binding
tube tube
450
100 100
50
Zero
tube
350
100
100
50
Standard
tube
250
100
100
100
50
Sample
tube
350
100
100
50
Incubate 3-5 h at 40C
200 200 200 200
Centrifuge and count charcoal pellet
Coefficients of variation were 27% for
the assay of plasma standards and 30%
for the assay of urine standards. These
relatively high values were thought to be
due to loss in BM activity during storage
over the period of repeated assays.
Assessment of BM inactivation by
25r
20 -
15r
10l
plasma was carried out by storage of
plasma standards at different tempera-
tures. Samples maintained at -20°C
(provided they were not frequently frozen
and thawed) retained complete BM
immunoreactivity for at least one month.
Those maintained at 40C retained full BM
immunoreactivity for up to 7 days, but
decreased slowly thereafter. At room
temperature, plasma BM levels remained
constant for 48 h but fell to 50% of their
original values after 8 days.
Human plasma and urine samples,
taken following BM therapy, were pooled
and stored in 200-,A aliquots at -20°C.
Aliquots were included in routine assays.
After 8 assays of the plasma pool, inter-
assay and within-assay variations were
both 12%. After 5 assays of the urine
pool, inter-assay variation was 20% and
within-assay variation 16%.
The assay results on plasma samples
TABLE II.-Drugs Exhibiting No Reaction
with Antiserum when Present in the
Assay in l-,ug Amounts
Methotrexate
Adriamycin
Vincristine
Cytosine arabinoside
Mercaptopurine
Fluorouracil
Procarbazine
Carbamezepine
Phenytoin
Nortriptyline
Lysergic acid
Morphine
Codeine
Amphetamine
Cocaine
Tetracycline
Promazine
Ephedrine
Nicotine
Trifluoperazine
Diphenhydramine
Lignocaine
Digoxin
Methadone
Diazepam
ng bleomycin
FIG. 1.-Standard curve for bleomycin.
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FjIa. 2. Plasma levels of bleomycin in 2 rabbits after an i.v. dose of 0 5 mg/kg given at time 0.
collected from rabbits following i.v. doses
of 0.5 and 1P0 mg/kg are shown in Figs. 2
and 3. Each of the 4 disappearance
curves showed two clearance phases over
the 3-h collection period. The calculated
half-lives for the first and second phases
were 9-12 and 30-42 min respectively.
BM concentrations were measured in
plasma and urine samples collected from
hospital patients undergoing treatment
with the drug. The plasma levels in
13
12
11
10
9
4
7
3
Patient 1, who had received 30 mg BM
i.v., are shown in Fig. 4. They indicate a
two-phase clearancewith estimatedplasma
half-lives of 43 and 140 min respectively.
Patient 2 received 15 mg of BM i.v.
Plasma BM levels and the amount of BM
recovered in the urine over the time of
specimen collection are shown in Fig. 5.
The plasma clearance in this individual
showed only a single phase with a half-
life of 150 min. Approximately 50%
90 120 180
Min
FiG. 3.-Plasma levels of bleomycin in 2 rabbits after an i.v. dose of 1 mg/kg given at time 0.J. D. TEALE, J. M. CLOUGH AND V. MARKS
Hours
Fi'G(. 4.-Plasma bleomycin levels in a patient after an i.v. dose of 30 mg given at time 0.
of the BM administered was recovered
in the urine during the first 7-5 h.
DISCUSSION
It is apparent from this study and an
earlier report by Broughton and Strong
(1976) that BM-protein conjugates are
highly immunogenic and capable of elicit-
ing high-titre high-avidity antisera in
immunizedanimals. Inadditiontostimu-
lating the production of antibodies in
sheep we have also raised high-titre
antisera in rabbits, but these have not
been considered in the present paper.
Since the therapeutic preparation of
BM is a mixture of A1, A2 and B2 com-
ponents, antisera were tested forreactivity
with the individual pure compounds.
HP/S/66-1C exhibited similar avidities
for the A2 and B2 components which
comprise 99% of the therapeutic mix-
ture. For this reason this antiserum was
used in the assay of specimens. Whether
the antiserum also cross-reacts with BM
metabolites and/or immunoreactive frag-
ments remains speculative, but the simi-
larity in plasma disappearance and urinary
excretion rates when measured by RIA
(Fig. 4) or bioassay (Ohnuma et al., 1974)
suggest that the RIA measures total
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FIG. 5.-Measurement of plasma and urinary
bleomycin levels in a patient after an i.v.
dose of 15 mg given at time 0.RADIOIMMUNOASSAY OF BLEOMYCIN 827
antibiotic activity, which is probably,
though not necessarily, equivalent to its
antitumour activity.
The antiserum (HP/S/66-1C) chosen
for use in the assay showed no cross-
reaction with several therapeutic drugs in
common use, nor with other antineo-
plastic agents often used in combination
with BM. The assay specificity for BM,
therefore, permits drug measurements to
be performed on untreated plasma and
urine samples.
The RIA of BM in plasma showed
good recovery values when the drug was
addedtonormalplasmaandurine. Varia-
tion in recovery occurred when specimens
were stored at 4°C for prolonged periods
or at room temperature for short periods.
It has been reported (Ohnuma et al.,
1974) that inactivation of BM by plasma
can occur during incubation at 37°C,
although this treatment had no effect
on urinary levels. The sensitivity of the
RIA is 8ng/ml, comparedwiththereported
range of 100-250 ng/ml for bacteriological
assay. Although the latter sensitivity
range is adequate for the measurement of
plasma levels shortly after the usual i.v.
dose of BM, the RIA offers a much simpli-
fied, more rapid and sensitive procedure.
Furthermore, tissue drug levels should
be detectable and measurable by the RIA
method, but so far we have no information
on this point.
The application ofRIA to the measure-
ment of BM levels during therapy should
provide a rapid method for continuous
control of patient dosage and should be
especially useful when applied to combina-
tion therapy in which BM is administered
together with other cytotoxic drugs such
as methotrexate (Aherne, Piall and Marks,
in preparation) and vincristine (Teale,
Clough and Marks, 1977) for which RIAs
have been produced.
We are grateful to the Cancer Research
Campaign for financial support. Speci-
mens from patients were kindly supplied
by Dr W. White and his staff at St Luke's
Hospital, Guildford.
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